Can a cancer vaccine plus hormone drugs slow prostate cancer?

NCT ID NCT05751941

Ongoing Disease control Sponsor: H. Lee Moffitt Cancer Center and Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding the immune-boosting drug Sipuleucel-T (Provenge) to standard hormone therapy can help men with advanced prostate cancer that is no longer responding to hormones alone. The trial involves 26 participants who will receive either Sipuleucel-T alone or with continued hormone drugs. The goal is to see if the combination activates the immune system more effectively.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sipuleucel-T (Provenge) combined with new hormonal agents (abiraterone, enzalutamide, or apalutamide)
What this could lead to: If successful, this combination could improve immune system activation against prostate cancer, potentially delaying disease progression.
What could go wrong: This is a small, early-phase trial with only 26 participants, so results may not apply broadly. The treatment may not improve outcomes and could cause side effects from the drugs or infusion.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC PROSTATE CANCER PROSTATE CANCER

Contacts and locations

Locations

Moffitt Cancer Center

Tampa, Florida, 33612, United States
Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.